CN1293877C - 神经营养性藤霉素类似物 - Google Patents

神经营养性藤霉素类似物 Download PDF

Info

Publication number
CN1293877C
CN1293877C CNB018228860A CN01822886A CN1293877C CN 1293877 C CN1293877 C CN 1293877C CN B018228860 A CNB018228860 A CN B018228860A CN 01822886 A CN01822886 A CN 01822886A CN 1293877 C CN1293877 C CN 1293877C
Authority
CN
China
Prior art keywords
compound
damage
disease
dysfunction
neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018228860A
Other languages
English (en)
Chinese (zh)
Other versions
CN1538843A (zh
Inventor
松冈信也
山路隆之
布鲁斯·戈尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd, Astellas Pharma Inc filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1538843A publication Critical patent/CN1538843A/zh
Application granted granted Critical
Publication of CN1293877C publication Critical patent/CN1293877C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB018228860A 2000-12-29 2001-12-31 神经营养性藤霉素类似物 Expired - Fee Related CN1293877C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
US60/258,500 2000-12-29

Publications (2)

Publication Number Publication Date
CN1538843A CN1538843A (zh) 2004-10-20
CN1293877C true CN1293877C (zh) 2007-01-10

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018228860A Expired - Fee Related CN1293877C (zh) 2000-12-29 2001-12-31 神经营养性藤霉素类似物

Country Status (18)

Country Link
EP (1) EP1353671A4 (cs)
JP (1) JP2004527472A (cs)
KR (2) KR100794204B1 (cs)
CN (1) CN1293877C (cs)
AR (1) AR035411A1 (cs)
AU (1) AU2002231277B2 (cs)
BR (1) BR0116762A (cs)
CA (1) CA2433384A1 (cs)
CZ (1) CZ20032060A3 (cs)
HU (1) HUP0302521A3 (cs)
IL (1) IL156664A0 (cs)
MX (1) MXPA03005941A (cs)
NO (1) NO20032913D0 (cs)
NZ (1) NZ527209A (cs)
PL (1) PL366301A1 (cs)
RU (1) RU2288716C2 (cs)
WO (1) WO2002053159A1 (cs)
ZA (1) ZA200305806B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
CA2554045A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
RU2521286C2 (ru) * 2008-07-23 2014-06-27 Новартис Аг Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани
WO2013124416A1 (en) * 2012-02-23 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033458A (zh) * 1987-12-09 1989-06-21 菲索斯有限公司 制备免疫抑制剂大环内酯的方法
WO1991004025A1 (en) * 1989-09-14 1991-04-04 Fisons Plc Novel macrocyclic compounds and novel method of treatment
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US537663A (en) * 1895-04-16 wubstee
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033458A (zh) * 1987-12-09 1989-06-21 菲索斯有限公司 制备免疫抑制剂大环内酯的方法
WO1991004025A1 (en) * 1989-09-14 1991-04-04 Fisons Plc Novel macrocyclic compounds and novel method of treatment
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators

Also Published As

Publication number Publication date
CN1538843A (zh) 2004-10-20
MXPA03005941A (es) 2005-02-14
RU2003123493A (ru) 2005-01-20
HUP0302521A3 (en) 2007-03-28
BR0116762A (pt) 2004-08-10
ZA200305806B (en) 2005-01-26
HUP0302521A2 (hu) 2003-11-28
AR035411A1 (es) 2004-05-26
PL366301A1 (en) 2005-01-24
NO20032913D0 (no) 2003-06-24
KR100794204B1 (ko) 2008-01-14
WO2002053159A1 (en) 2002-07-11
NZ527209A (en) 2005-09-30
EP1353671A1 (en) 2003-10-22
KR20070030331A (ko) 2007-03-15
AU2002231277B2 (en) 2006-11-30
EP1353671A4 (en) 2004-07-14
CA2433384A1 (en) 2002-07-11
RU2288716C2 (ru) 2006-12-10
CZ20032060A3 (cs) 2004-01-14
JP2004527472A (ja) 2004-09-09
KR20040007431A (ko) 2004-01-24
IL156664A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
JP7082186B2 (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
Yin et al. Taxol-modified collagen scaffold implantation promotes functional recovery after long-distance spinal cord complete transection in canines
CN1228024A (zh) K－252a衍生物用于治疗外周或中枢神经系统疾病以及细胞因子超量生产的用途
HK1255075A1 (zh) 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
Hauber et al. Dopamine D1 or D2 receptor blockade in the globus pallidus produces akinesia in the rat
TW524690B (en) Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
JP5243428B2 (ja) 神経細胞の損傷を減少させるための薬学的組成物
CN1538843A (zh) 神经营养性藤霉素类似物
Faurbye The structural and biochemical basis of movement disorders in treatment with neuroleptic drugs and in extrapyramidal diseases
US6284771B1 (en) Method for treating schizophrenia
CN1708297A (zh) 用于预防和/或治疗抗癌剂诱导的外周神经病的乙酰基－l－肉碱
HK1041226A1 (zh) 治療胃-食管返流性疾病的方法和組合物
AU2002231277A1 (en) Neurotrophic tacrolimus analogs
CN1284790C (zh) 山茱萸提取物、其提取方法以及在制备药物及保健品中的用途
JPS60252416A (ja) Ｃｄｐコリン組成物
US20040077676A1 (en) Neurotrophic tacrolimus analogs
CN115103676A (zh) 使用普利多匹定和另一种激活剂治疗肌萎缩侧索的组合疗法
KR20260049790A (ko) 신경 손상 복구 제품의 제조에서의 2가 금속 락테이트의 용도
CN1256086C (zh) 5－羟甲基糠醛类用于制备神经系统用药的用途
DE60215525T2 (de) Kombination aus quetiapin und zolmitriptan
US20060276460A1 (en) Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
BR112020004023A2 (pt) uso de um composto e composição farmacêutica ou suplemento nutricional
EP3362059B1 (en) New combination therapies for treating neurological damage
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
CN1270727C (zh) 一种治疗脊髓损伤的治疗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD.

Effective date: 20060428

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060428

Address after: Tokyo, Japan

Applicant after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka City, Osaka of Japan

Applicant before: Fujisawa Pharmaceutical Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070110

Termination date: 20100201